Catalent today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.

Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.

Catalent announced that its clinical supply experts will be participating in upcoming Global Clinical Supplies Group (GCSG) events, discussing cell and gene therapy supply chains, direct-to-patient (DTP) services, and just-in-time delivery models.

Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.

Catalent has signed an agreement with Cybin Inc to apply Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.

Catalent today announced Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy.

As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.

Catalent today announced that two of its clinical supply experts will be participating in upcoming digital events, Clinical Trial Supply Europe and Clinical Trial Supply Roundtable Forum 2021.

EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.